Technological entrepreneurship support by BIC Gipuzkoa and practical experience (start-up)
CIC nanoGUNE Seminars
- Speaker
-
Esther Paguey, BIC BERRILAN, Project Manager
- When
-
2019/11/25
12:00 - Place
- nanoGUNE seminar room, Tolosa Hiribidea 76, Donostia - San Sebastian
- Add to calendar
-
iCal
This seminar is organized in the framework of nanoGUNE’s Training and
Technology Transfer plans, and is addressed to all nanoGUNE researchers with
the aim of presenting some important grants and services offered by the **BIC
Gipuzkoa**.
BIC Gipuzkoa offers guidance on the processes of creating new, innovative
and/or technology based companies. They act as facilitators in the process of
creating new companies, as well as as an active agent in the support and
promotion of entrepreneurial culture in Gipuzkoa. Since its creation in 1993,
it has become an important engine in regional development, with capacity to
anticipate, adapt and respond to the concrete needs of new entrepreneurs and
businesses in Gipuzkoa, inspiring innovation, qualification and consolidation
of the business activity of its geographic surroundings, and in extensive
collaboration with the Technology Centers, Private and Public Institutions and
Universities.
In this seminar, **BIC Gipuzkoa** will introduce the resources they are
offering to boost entrepreneurial ideas within the research community,
including grants, trainings, and other services. Furthermore, they will also
present some real experiences of regional start-up companies, such as Onena
Medicines S.L.
We will also have the pleasure to listen to **Neethan A. Lobo** , co-founder
of Onena Medicines S.L., about his experience as a entrepreneur. Neethan Lobo
(PhD) has over 20 years of scientific discovery experience and 8 years of
industry experience. After working for a few years at GlaxoSmithKline in
microbiology drug discovery, Neethan completed his doctoral training at the
University of Michigan studying normal and cancer stem cell biology in the
laboratory of Dr. Michael F. Clarke, the pioneer of cancer stem cells in solid
tumors. During his post-doctoral work at Stanford University, Neethan co-
invented a state-of-the-art single cell transcriptional platform that he used
to uncover mechanisms that drive drug resistance. This work served as the
basis of the spin-out company Quanticel Pharmaceuticals, Inc., where Neethan
spearheaded the biological modeling and platform development. After
Quanticel?s successful acquisition by Celgene Corporation for $100 million USD
upfront and $385 million in future milestones, Neethan worked at Celgene
Quanticel Research in drug discovery focusing on the development of drug
discovery models and head of target validation. Neethan then joined DiscoverX
to lead their oncology efforts for their BioMAP division, a major contributing
factor to DiscoverX?s successful acquisition by Eurofins, the world?s largest
drug services provider. Neethan then joined Unity Biotechnology, where he
worked as a program, alliance and portfolio manager for early phase R&D
projects originating from the Frontier sciences group, led by the President of
the company. Together with his co-founder Maider Zabala Ugalde, Neethan went
on to form Onena Medicines S.L. in 2019 to initiate development of antibody
therapeutics to treat oncology and other selected rare disease indications.
**Host:** I. Otegui